Oncologic Safety of Gonadotropin-Releasing Hormone Agonist for Ovarian Function Protection During Breast Cancer Chemotherapy-Reference-Cited by-同舟云学术

Oncologic Safety of Gonadotropin-Releasing Hormone Agonist for Ovarian Function Protection During Breast Cancer Chemotherapy

Published:2018-10 Issue:5 Volume:18 Page:e1165-e1172
ISSN:1526-8209
Container-title:Clinical Breast Cancer
language:en
Short-container-title:Clinical Breast Cancer

Author:

Kim Hee Jeong,Lee Moo Hyun,Lee Jeong Eon,Park Seho,Lee Eun Sook,Kang Yong Joon,Shin Hae Na,Kim Seung Il,Lee Jun Ho,Im Seock Ah,Ahn Sei Hyun,Lee Keun Seok,Sohn Joohyuk,Kim Seonok^ORCID,Nam Seok Jin,Han Wonshik

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference27 articles.

1. Effect of luteinizing hormone–releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study;Gerber;J Clin Oncol,2011

2. Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer;Munster;J Clin Oncol,2012

3. ZORO study: discrepancy between the conclusion and the results;Blumenfeld;J Clin Oncol,2011

4. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy;Moore;N Engl J Med,2015

5. What lies behind chemotherapy-induced amenorrhea for breast cancer patients: a meta-analysis;Zhao;Breast Cancer Res Treat,2014

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chemotherapy combined with endocrine therapy: Old wine in a new bottle?;Clinical Breast Cancer;2024-08

2. Fertility Preservation :A Big Dilemma For Patients With Breast Cancer;Journal of Breast Diseases;2024-03-01

3. Ovarian Function and Fertility Preservation in Breast Cancer: Should Gonadotropin-Releasing Hormone Agonist be administered to All Premenopausal Patients Receiving Chemotherapy?;Clinical Medicine Insights: Reproductive Health;2019-01